van Breugel Henrica N A M, Gelsomino Sandro, Lozekoot Pieter W J, Accord Ryan E, Lucà Fabiana, Parise Orlando, Crijns Harry J G M, Maessen Jos G
Cardiothoracic Surgery and Cardiology, University Hospital, Maastricht, Netherlands.
Interact Cardiovasc Thorac Surg. 2014 Mar;18(3):313-20. doi: 10.1093/icvts/ivt522. Epub 2013 Dec 13.
We investigated real-life oral anticoagulation (OAC) treatment after surgical ablation and examined its adherence to current recommendations. We also explored factors related to OAC use preoperatively and at follow-up.
One hundred and fifteen patients with atrial fibrillation (AF) were evaluated during 12-month follow-up after surgery. Patients were divided into two categories according to the congestive heart failure, hypertension, age ≥75 years, diabetes and prior stroke [or transient ischaemic attack or thromboembolism] (CHADS2) score: 60 patients were assigned to the high-risk group (CHADS2 score ≥2) and 55 to the low-risk group (CHADS2 score ≤1). OAC use was defined as guideline adherent, undertreatment or overtreatment.
Baseline overall guideline adherence was 62%. OAC was underprescribed in high-risk patients and overprescribed in low-risk patients (both, P < 0.001). The only factor associated with OAC use after logistic regression analysis were age >75 years (P = 0.01) and preoperative AF > paroxysmal (P = 0.013). Overall guideline adherence at 12-month follow-up showed a trend towards a better adherence in the sinus rhythm (SR) subgroup (74% vs 55%, P = 0.02). OAC was underprescribed in high-risk patients and overprescribed in low-risk patients (both P < 0.001). After logistic regression analysis, preoperative OAC use (P = 0.007) and other indications for OAC (P = 0.01) were predictors of anticoagulation treatment.
Real-life OAC prescription in AF patients showed a moderate guideline adherence, with high-risk patients being undertreated and low-risk patients being overtreated. These findings stress the importance that antithrombotic treatment in patients undergoing AF surgery needs to be critically re-evaluated.
我们调查了手术消融术后的实际口服抗凝(OAC)治疗情况,并检查了其对当前建议的遵循情况。我们还探讨了术前和随访时与使用OAC相关的因素。
115例房颤(AF)患者在术后12个月的随访期间接受评估。根据充血性心力衰竭、高血压、年龄≥75岁、糖尿病和既往卒中[或短暂性脑缺血发作或血栓栓塞](CHADS2)评分将患者分为两类:60例患者被分配到高危组(CHADS2评分≥2),55例患者被分配到低危组(CHADS2评分≤1)。OAC的使用被定义为符合指南、治疗不足或治疗过度。
基线时总体指南遵循率为62%。高危患者OAC处方不足,低危患者OAC处方过度(均P<0.001)。逻辑回归分析后,与使用OAC相关的唯一因素是年龄>75岁(P=0.01)和术前房颤>阵发性房颤(P=0.013)。12个月随访时的总体指南遵循率显示,窦性心律(SR)亚组有更好的遵循趋势(74%对55%,P=0.02)。高危患者OAC处方不足,低危患者OAC处方过度(均P<0.001)。逻辑回归分析后,术前使用OAC(P=0.007)和OAC的其他指征(P=0.01)是抗凝治疗的预测因素。
房颤患者的实际OAC处方显示出对指南的适度遵循,高危患者治疗不足,低危患者治疗过度。这些发现强调了对接受房颤手术患者的抗血栓治疗进行严格重新评估的重要性。